Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Am J Transplant. 2019 Jan 9;19(5):1305–1314. doi: 10.1111/ajt.15216

Figure 2: Inhibitors target specific nodes in the PI3K/Akt/mTOR pathway in EBV-positive B cell lymphoma (AB5).

Figure 2:

(A) Inhibitors (in rectangles) were chosen which block specific nodes in the PI3K/Akt/mTOR pathway. Schematic shows intended targets of CAL-101 (PI3Kδ inhibitor), MK-2206 (Akt inhibitor), rapamycin (mTOR inhibitor), and AZD-2014 (mTORC1/mTORC2 dual inhibitor). (B) Western blot analysis of phosphoproteins (pAKT, pS6K) and total proteins (Akt, S6K, β-actin) in AB5 (EBV+ PTLD cell line) after treatment with rapamycin (100 nM) and with or without CAL-101 (1 µM) and MK-2206 (1 µM), and AZD-2014 (1 µM). β-actin was used as a loading control (representative image from 3 experiments). (C) Western blot of cell lysates from AB5 cultured without or with the indicated inhibitors (rapamycin, CAL-101, MK-2206, and AZD-2014) were probed for activation of alternative signaling pathways (p38 MAPK, p44/42 ERK1/2, and STAT1). β-actin was used as a loading control